Epigral Ltd

- The transcript does not mention any current or planned fundraising through debt or equity. - The company is focusing on ongoing capex projects like doubling CPVC and ECH capacities and wind-solar hybrid power plant using internal resources. - They have also acquired land for future expansion and are evaluating new projects, but details or plans about raising capital through debt or equity have not been disclosed. - Interest cost discussion indicates existing debt management but no mention of new borrowing. - Overall, there is no explicit indication of fresh fundraising activities in the current or near future based on the transcript.

- Epigral is currently executing capex projects including doubling the capacity of CPVC resin and Epichlorohydrin plants. - A 19.8 MW wind-solar hybrid power plant expansion is underway, expected to add to a total of 38 MW hybrid capacity. - Ongoing expansion capex for FY '26 is around INR 450 crores, with roughly INR 120 crores already spent; a similar capex range (~INR 400-450 crores) is expected for FY '27. - Company is evaluating a project within the existing complex to optimize infrastructure; this will be the last at this site. - They have acquired ~100 acres near the existing complex at Dahej for 7 years of growth, where they plan to develop new chemistry aligned with import substitution to drive double-digit growth and good ROCE. - Details of this new expansion are being finalized and will be announced once approved by the Board, likely in the next couple of quarters.

- Epigral aims for consistent growth driven by expansion and diversification into multiproducts serving various industries. - Revenue contribution from derivatives and specialty business is targeted to increase from 50% in Q1 FY26 to 70% by FY28. - The recently commissioned Chlorotoluene value chain is expected to generate sizable revenue by the end of FY26, with commercial order clarity by Q4 FY26. - Expansion projects including doubling capacities of CPVC resin and Epichlorohydrin (ECH) are on schedule, expected to boost volumes and sales in FY27 and FY28. - New product evaluations and projects on existing and newly acquired land at Dahej aim to add growth beyond 2028, focusing on import substitution chemicals with expected double-digit CAGR (~12-13%) over 10 years. - Demand slowdown due to monsoon is temporary; demand expected to pick up from Q3 FY26 onwards. - Overall growth is underpinned by operational efficiency and strategic infrastructure investments.

- Epigral targets consistent growth driven by expansion and diversification into multiproduct segments catering to various industries. - The derivatives and specialty business revenue contribution aims to increase from 50% in Q1 FY'26 to 70% by FY'28. - Capex projects including doubling capacity of CPVC resin, Epichlorohydrin (ECH) plant, and a 19.8 MW wind-solar hybrid power plant are on schedule, expected to positively impact earnings. - The newly commissioned Chlorotoluene value chain is anticipated to generate sizable revenue by end FY'26, contributing to growth in FY'27 and FY'28. - Improvement in operational efficiencies and optimized plant utilization (post maintenance) expected from Q3 FY'26 supports margin stability and profit growth. - Shift to new tax regime with a lower tax rate (25.17%) improves profit after tax and EPS going forward. - Expansion projects on existing and new land parcels evaluated to sustain double-digit CAGR growth beyond 2028 with good ROCE.

- Chlorotoluene plant is currently in trial stage, with commercial orders expected to start from Q4 FY '26; exact revenue from this is not yet specified but clarity expected by Q4. - Pipeline customers for chlorine include Meghmani company and other nearby companies supplied via pipeline; chlorine is partly sold through pipeline and partly to the general market. - No specific details provided about a disclosed orderbook or pending orders for other products in this transcript. - Trial orders for Chlorotoluenes are ongoing, commercial scale ramp-up anticipated by end of Q3 FY '26. - The company expects consistent growth in its multiproduct pipeline aligned with expansion and diversification strategies.